Zymeworks (ZYME)
(Delayed Data from NSDQ)
$8.33 USD
+0.07 (0.85%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $8.31 -0.02 (-0.24%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Zymeworks Inc. [ZYME]
Reports for Purchase
Showing records 1 - 20 ( 54 total )
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
HERIZON-GEA-01 Data in Late 2024; 2023 Financials; Raising PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Topline HERIZON-GEA-01 Data Expected in 2024; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ZYME 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Multiple Datasets Presented; 3Q23 Financial Results; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Financial Results Reported; Lengthy Cash Runway; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
HERIZON-BTC-01 Data Presented at ASCO; 1Q23 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Financial Results; Bispecific Collaboration Concluded; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Zanidatamab + Chemo Phase 2 1L GEA Results Presented; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Jazz Exercises Zanidatamab Option; Lowering PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
R&D Day Takeaways; Zanidatamab Option Agreement; Downgrade to Neutral; Price Target Lowered to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Multiple Data Releases Slated for 2H22; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Zanidatamab Combo Regimens Front-Line Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R